← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neumedicines, Inc.
Pasadena, CA
$3,005,151
Total funding
4
Grants
Funding over time
peak $1.1M · FY2006–16$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,005,151 · 4
By mechanism
R44$1,505,508 · 1
R42$1,002,076 · 1
R41$497,567 · 2
Investigators at Neumedicines, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase IIa Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patients Receiving Radiotherapy$1,088,333
R44 · FY2015 · CA
A Phase IIa Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patients Receiving Radiotherapy$417,175
R44 · FY2016 · CA
Retroviral Vectors for Safe and Efficacious Gene Therapy$366,732
R42 · FY2008 · RR
Retroviral Vectors for Safe and Efficacious Gene Therapy$329,438
R42 · FY2007 · RR
Retroviral Vectors for Safe and Efficacious Gene Therapy$209,395
R42 · FY2006 · RR
IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy$197,568
R41 · FY2007 · CA
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$187,491
R41 · FY2006 · CA
Uses of IL-12 as a Hematological Adjuvant Cancer Therapy$112,508
R41 · FY2006 · CA
Retroviral Vectors for Safe and Efficacious Gene Therapy$96,511
R42 · FY2006 · RR